Drug
LU Ag22515
LU Ag22515: highest development phase Phase 1, developed by Lundbeck. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Lundbeck
Trials
| Drug | Phase | Indication |
|---|---|---|
| Lu AG22515 NCT06557850 | Phase 1 | Thyroid Eye Disease |
Latest
No recent events.
Follow LU Ag22515 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.